Poolbeg Pharma plc – Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
12 March 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board.
Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome (“CRS”).
